Korean Circ J.  1992 Feb;22(1):113-120. 10.4070/kcj.1992.22.1.113.

Clinical Efficacy of Pravastatin in Patients with Hypercholesterolemia

• Kim JS
• Han KH
• Park SW
• Bang JK
• Hong SK
• Sohn DW
• Oh BH
• Lee MM
• Park YB
• Choi YS
• Seo JD
• Lee YW

• KMID: 2093361
• DOI: http://doi.org/10.4070/kcj.1992.22.1.113

Abstract

BACKGROUND
This study was designed to evaluate the clinical efficacy of pravastatin, HMG-CoA reductase inhibitor, in patients with hypercholesterolemia. Methods and
RESULTS
Pravastatin 5 mg was administered twice daily for 12 weeks in twenty five patients(12 male, 13 female) with hypercholesterolemia(>240 mg/dl). Compared with pretreatment levels, pravastatin significantly decreased levels of total cholesterol(281+/-41mg/dl versus 218+/-31mg/dl) by 22% and LDL-cholesterol(199+/-46mg/dl versus 137+/-37mg/dl) by 31% with significantly decreased total-cholesterol/HDL-cholesterol ratio(7.1+/-3.0 versus 5.1+/-1.6) and LDL-cholesterol/HDL-cholesterol ratio(5.1+/-2.5 versus 3.3+/-1.4) (p<0.005, respectively). During pravastatin treatment, the level of Apo B(164+/-38mg/dl versus 123+/-20mg/dl) was decreased significantly by 24% with significantly decreased Apo B/Apo A-1 ratio(1.4+/-0.5 versus 1.0+/-0.3) (p<0.005, respectively). No serious side effects were found.
CONCLUSIONS
Results from the present study show that pravastatin is an effective and well-tolerated cholesterol-lowering agent.

Keyword

Hypercholesterolemia; Pravastatin

MeSH Terms

Humans
Hypercholesterolemia*
Male
Oxidoreductases
Pravastatin*
Oxidoreductases
Pravastatin